Repligen (NASDAQ:RGEN) Given New $170.00 Price Target at Canaccord Genuity Group

Repligen (NASDAQ:RGEN) had its price target upped by Canaccord Genuity Group from $165.00 to $170.00 in a report released on Friday,Benzinga reports. The firm currently has a hold rating on the biotechnology company’s stock.

Several other brokerages also recently weighed in on RGEN. TD Cowen assumed coverage on Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 price target for the company. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. HC Wainwright reaffirmed a “buy” rating and set a $180.00 price target on shares of Repligen in a research note on Friday. Wolfe Research initiated coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. Finally, Canaccord Genuity Group began coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. One analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $181.00.

Repligen Stock Down 2.3 %

RGEN opened at $158.99 on Friday. The stock has a market capitalization of $8.91 billion, a P/E ratio of -311.75, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen has a one year low of $113.50 and a one year high of $203.13. The business’s 50-day simple moving average is $155.22 and its 200-day simple moving average is $148.59.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Analysts anticipate that Repligen will post 1.72 EPS for the current year.

Institutional Trading of Repligen

Hedge funds have recently bought and sold shares of the company. GTS Securities LLC acquired a new position in Repligen in the 4th quarter valued at $264,000. Gordian Capital Singapore Pte Ltd acquired a new stake in shares of Repligen during the fourth quarter worth $259,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Repligen by 12.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 235,343 shares of the biotechnology company’s stock valued at $33,875,000 after purchasing an additional 26,733 shares during the last quarter. Two Sigma Advisers LP increased its stake in Repligen by 6.7% in the fourth quarter. Two Sigma Advisers LP now owns 134,800 shares of the biotechnology company’s stock valued at $19,403,000 after purchasing an additional 8,500 shares during the last quarter. Finally, Raiffeisen Bank International AG acquired a new stake in Repligen in the 4th quarter worth about $29,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.